Dan Peer
Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University (TAU). He is also the Vice President for Research and Development at Tel Aviv University, the biggest research university in Israel. In 2017 he co-founded and acts as the Managing Director of SPARK Tel Aviv, Center for Translational Medicine. From 2016-2020 he was the Chair of Tel Aviv University Cancer Biology Research Center. He holds more than 120 pending and granted patents. Prof. Peer is a scientific advisory board member in more than 15 companies and on the  scientific advisory board of 20 journals. He is a past President of the Israeli Chapter of the Controlled Release Society, and a Past Member of the Board of the Israel Young Academy of Science. Research work. Prof. Peer's work was among the first to demonstrate immunomodulation through a systemic delivery of RNA-loaded targeted nanocarriers. He pioneered the use of RNAi to reprogram immune cells and discover new therapeutic modalities. In addition, his lab was the first to show systemic, cell specific delivery of mRNA in an animal. Through this method they have induced therapeutic gene expression of desired  proteins (including novel approaches for high efficiency therapeutic genome editing), which has enormous implications in cancer, rare genetic diseases and infection diseases. Research focus. The Peer lab is designing novel methodologies to manipulate cells' function in vivo, using targeted, safe, lipid nanoparticles. They are utilizing nanotechnology tools to generate novel therapeutic strategies for inflammatory diseases, rare genetic diseases and cancers. The lab is combining multidisciplinary approaches including immunology, cell and molecular biology, genetics, protein engineering, material sciences, nanotechnology and computational techniques for drug discovery. In addition, they are designing highly selective targeted nanocarriers able to reprogram cells in a discerning  manner, with an ultimate goal to translate the findings into clinical settings.